Cost-effectiveness of a genetic test for breast cancer risk

Cancer Prevention Research

Volumn 6, Issue 12, 2013, Pages 1328-1336

  Folse, Henry J ^a   Green, Linda E ^b   Kress, Andrea ^a   Allman, Richard ^c   Dinh, Tuan A ^a  

^a Archimedes Inc   (United States)

^b DOMINICAN UNIVERSITY OF CALIFORNIA   (United States)

^c Genetic Technologies Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; FEMALE; GENETIC RISK; GENETIC SCREENING; HIGH RISK PATIENT; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BREAST NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; GENETIC TESTING; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 84890460170     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0056     Document Type: Article

References (40)

1. Easton DF, Pooley KA, Dunning AM, Pharoah PDP, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
2. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007;39:865-9.
3. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008;40:703-6.
4. Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358:2796-803.
5. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008;14:8000-9.
6. Saslow D, Boetes C, Burke W, Harms S, Leach M, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
7. Gail MH, Brinton LA, Byar DP, Corle DL, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
8. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-51.
9. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30.
10. National Cancer Institute. Breast Cancer Risk Assessment Tool. National Cancer Institute; 2011. Available from: http://www.cancer.gov/bcrisktool/.
11. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008;100:1037-41.
12. Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 2009;101:959-63.
13. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010;362:986-93.
14. Mealiffe ME, Stokowski RP, Rhees BK, Prentice RL, Pettinger M, Hinds DA. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst 2010;102:1618-27.
15. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems-the mathematical formulation. J Biomed Inform 2002;35:37-50.
16. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-74.
17. Noah-Vanhoucke J, Green LE, Dinh TA, Alperin P, Smith RA. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Cancer 2011;117:3322-31.
18. Surveillance, Epidemiology, and End Results (SEER) Data, 1973-2007 [database on the Internet]. National Cancer Institute 2007.
19. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, et al. The American cancer society cancer prevention study II nutrition cohort. Cancer 2002;94:2490-501.
20. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600-7.
21. Centers for Disease Control and Prevention and National Center for Health Statistics. National Health and Nutrition Examination Survey Data 1999-2006. 2006 [cited 2008 September].
22. Pinsky PF, Kramer BS, Reding D, Buys S. Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol 2003;157:792-9.
23. NCI-funded Breast Cancer Surveillance Consortium (U01CA63740 UC, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040, HHSN261201100031C). 2009 [cited 2009 01/08]; Available from: http://breastscreening.cancer.gov/data/mammography-data.html.
24. Warner E, Messersmith H, Causer PA, Eisen A, Shumak R, Plewes DB. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148:671-9.
25. Warner E, Plewes DB, Hill K, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-25.
26. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
27. Kriege M, Brekelmans CTM, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat 2006;100:109-19.
28. Abramovici G, Mainiero MB. Screening breast MR imaging: comparison of interpretation of baseline and annual follow-up studies. Radiology 2011;259:85-91.
29. Services CfMaM. Physicians Fee Schedule. 2012 [cited 2012 Apr 12]; Available from: http://www.cms.gov/apps/physician-fee-schedule/.
30. Warren Burhenne LJ, Coldman AJ, Kan L, editors. Organized Breast Cancer Screening in British Columbia: The Screening Mammography Program of British Columbia. Seminars in Breast Disease; Elsevier; 2007.
31. Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 2007;4:643-56.
32. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20.
33. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006;98:774-82.
34. Graubard BI, Freedman AN, Gail MH. Five-year and lifetime risk of breast cancer among U.S. subpopulations: implications for magnetic resonance imaging screening. Cancer Epidemiol Biomarkers Prev 2010;19:2430-6.
35. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006;295:2374-84.
36. Moore SG, Shenoy PJ, Fanucchi L, Tumeh JW, Flowers CR. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res 2009;9;9.
37. Lee JM, McMahon PM, Kong CY, Kopans DB, Ryan PD, Ozanne EM, et al. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology 2010;254:793-800.
38. Classe JS. Genes and the supremes: will the supreme court uphold patents for isolated gene sequences? Tex Tech L Rev 2013;45:533-65.
39. Viswanathan KS, Lemaire J, Withers K, Armstrong K, Baumritter A, Hershey JC, et al. Adverse selection in term life insurance purchasing due to the BRCA1/2 genetic test and elastic demand. J Risk Insur 2007;74:65-86.
40. Gierisch JM, Earp JA, Brewer NT, Rimer BK. Longitudinal predictors of nonadherence to maintenance of mammography. Cancer Epidemiol Biomarkers Prev 2010;19:1103-11.